company background image
688321 logo

Shenzhen Chipscreen Biosciences SHSE:688321 Stock Report

Last Price

CN¥18.24

Market Cap

CN¥7.4b

7D

-4.0%

1Y

5.4%

Updated

22 Mar, 2025

Data

Company Financials +

Shenzhen Chipscreen Biosciences Co., Ltd.

SHSE:688321 Stock Report

Market Cap: CN¥7.4b

688321 Stock Overview

Shenzhen Chipscreen Biosciences Co., Ltd. More details

688321 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Shenzhen Chipscreen Biosciences Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Shenzhen Chipscreen Biosciences
Historical stock prices
Current Share PriceCN¥18.24
52 Week HighCN¥25.99
52 Week LowCN¥15.15
Beta0.65
1 Month Change0.94%
3 Month Change-8.11%
1 Year Change5.37%
3 Year Change-29.30%
5 Year Change-60.11%
Change since IPO-80.86%

Recent News & Updates

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Price Is Out Of Tune With Revenues

Feb 06
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Price Is Out Of Tune With Revenues

Recent updates

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Price Is Out Of Tune With Revenues

Feb 06
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Price Is Out Of Tune With Revenues

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) 50% Price Boost Is Out Of Tune With Revenues

Oct 08
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) 50% Price Boost Is Out Of Tune With Revenues

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Price In Tune With Revenues

Aug 21
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Price In Tune With Revenues

We Think Shenzhen Chipscreen Biosciences (SHSE:688321) Has A Fair Chunk Of Debt

Jun 04
We Think Shenzhen Chipscreen Biosciences (SHSE:688321) Has A Fair Chunk Of Debt

Investors Appear Satisfied With Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Prospects As Shares Rocket 26%

Apr 24
Investors Appear Satisfied With Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Prospects As Shares Rocket 26%

Solid Earnings May Not Tell The Whole Story For Shenzhen Chipscreen Biosciences (SHSE:688321)

Apr 05
Solid Earnings May Not Tell The Whole Story For Shenzhen Chipscreen Biosciences (SHSE:688321)

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Shares Climb 30% But Its Business Is Yet to Catch Up

Mar 06
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Shares Climb 30% But Its Business Is Yet to Catch Up

Shareholder Returns

688321CN PharmaceuticalsCN Market
7D-4.0%-0.8%-2.1%
1Y5.4%-0.5%11.6%

Return vs Industry: 688321 exceeded the CN Pharmaceuticals industry which returned -0.6% over the past year.

Return vs Market: 688321 underperformed the CN Market which returned 11.6% over the past year.

Price Volatility

Is 688321's price volatile compared to industry and market?
688321 volatility
688321 Average Weekly Movement4.4%
Pharmaceuticals Industry Average Movement4.7%
Market Average Movement6.0%
10% most volatile stocks in CN Market10.2%
10% least volatile stocks in CN Market3.4%

Stable Share Price: 688321 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 688321's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20011,187Xian-Ping Luwww.chipscreen.com

Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of original small molecule drugs. The company develops precursor compounds and original new drug product lines for the treatment of human diseases in five therapeutic areas, including cancer, metabolic diseases, autoimmune disorders, central nervous system disorders, and antivirals. It is developing chidamide, a subtype-selective benzamide inhibitor of histone deacetylase (HDAC) primarily targeting subtypes 1, 2, 3 of class I HDAC; chiglitazar, a new-generation insulin sensitizing candidate drug for the treatment of type 2 diabetes mellitus; and chiauranib, an aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor.

Shenzhen Chipscreen Biosciences Co., Ltd. Fundamentals Summary

How do Shenzhen Chipscreen Biosciences's earnings and revenue compare to its market cap?
688321 fundamental statistics
Market capCN¥7.44b
Earnings (TTM)-CN¥114.57m
Revenue (TTM)CN¥657.95m

11.3x

P/S Ratio

-64.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688321 income statement (TTM)
RevenueCN¥657.95m
Cost of RevenueCN¥0
Gross ProfitCN¥657.95m
Other ExpensesCN¥772.52m
Earnings-CN¥114.57m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Apr 26, 2025

Earnings per share (EPS)-0.28
Gross Margin100.00%
Net Profit Margin-17.41%
Debt/Equity Ratio78.9%

How did 688321 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/22 03:20
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Shenzhen Chipscreen Biosciences Co., Ltd. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhizhong JingChina Merchants Securities Co. Ltd.
Bin WuChina Merchants Securities Co. Ltd.
Yinglan ShuHaitong International Research Limited